18007 Sky Park Circle
About BiogennixBiogennix is a leading developer of osteobiologic products specifically designed for spine fusion. Founded in 2009, we are led by a team of scientists and industry veterans committed to delivering unique products for bone regeneration. Biogennix designs, manufactures and distributes all of its products from its Irvine facilities located in the heart of Southern California’s “Technology Coast.”
YEAR FOUNDED: 2009
CTO: Tim Bumbalough
11 articles with Biogennix
Irvine-based Biogennix, a market leader in advanced bone regeneration technology, announced that its DirectCell Advanced Bone Grafting System has already been used in over 500 cases.
Biogennix Receives FDA Clearance for Expanded Use of Agilon Moldable Bone Grafting Solution in Spine Procedures
Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an expanded indication for its AgilonTM moldable bone grafting product.
The company and its employees chose to donate a Wednesday afternoon supporting Second Harvest Food Bank of Orange County.
Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft products used for bone fusion procedures, exhibited its TrelCor™ technology at the North American Spine Society annual meeting last week, including its newest product, Agilon™, which was recently cleared by the FDA for use in bone fusions.
Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone grafting products used for bone fusion procedures, announced today that its July performance was the best in the company’s history.
Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures spent the morning at the beach last Friday – but it was not a surfing or sunbathing expedition.
Company Also Expands Sales, Marketing and R&D Teams
Biogennix announced today that it saw 33% growth for the first quarter of 2018.
The company closed the year with 47% growth, the broadest increase the company has experienced in its history.
Irvine-based Biogennix announced today that it is expanding its distribution efforts for its novel bone graft substitutes, Morpheus and osteoSPAN to full national distribution.